Encouraging New Developments Reported on Investigational Therapy, CLN-978, for Treatment of Systemic Lupus Erythematosus
New data presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress of the investigational therapy, CLN-978, currently in Phase 1 study show clinical benefit, including remissions, after a single target dose of CLN-978 in people with refractory systemic lupus erythematosus (SLE) and difficult-to-treat rheumatoid arthritis (RA).
CLN-978 is a novel T cell engager designed to target and destroy disease-causing B cells and has the potential to be a convenient, off-the-shelf, subcutaneously delivered treatment option. Early results confirm deep, dose-dependent B cell depletion in peripheral blood and tissue. The favorable safety profile and clear dose-dependent response reinforce the potential of CLN-978 as a disease-modifying therapy for challenging autoimmune diseases.
Ongoing studies of multi-dose regimens aim to advance CLN-978 quickly through global clinical development to bring this new option to people with SLE and RA. Further data, including data from the first RA multi-dose cohort, will be shared at an Immunology Day hosted by Cullinan Therapeutics on June 10. Learn more about T-cell engagers here. Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about treatments being studied for lupus.
Interested in getting research like this straight to your inbox? Subscribe to our monthly Inside Lupus Research email for all the latest.